One step closer to access to Lutathera for pNETs patients!

The pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with Advanced Accelerator Applications for Lutathera (lutetium 177 dotatate) in pNETs  concluded on 2023-10-17.

Negotiation Status: Concluded with an LOI

Lutathera (lutetium 177 dotatate) – Indication(s): For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor (SSR)–positive pancreatic neuroendocrine tumours (pNETs) in adults whose disease has progressed after treatment with a somatostatin analogue (SSA), unless there is a contraindication or intolerance.

CNETS is now calling on all provinces to update their reimbursement criteria in a timely manner to provide access to Lutathera for pNETs patients!